Atara biotherapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 74,055 restricted stock units of atara's common stock to 16 newly hired employees and stock options to purchase an aggregate of 59,869 shares of atara's common stock to five such newly hired e
ATRA Ratings Summary
ATRA Quant Ranking